Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway

详细信息    查看全文

• 作者：Fernanda Marconi Roversi^a ; Fernando Vieira Pericole^a ; Joã ; o Agostinho Machado-Neto^a ; Adriana da Silva Santos Duarte^a ; Ana Leda Longhini^a ; Flá ; via Adolfo Corrocher^a ; Bruna Palodetto^a ; Karla Priscila Ferro^a ; Renata Giardini Rosa^a ; Mariana Ozello Baratti^a ; Sergio Verjovski-Almeida^b ; Fabiola Traina^a ; ¹ ; Alessio Molinari^c ; Maurizio Botta^c ; Sara Teresinha Olalla Saad^a ; ^{sara@unicamp.br}
• 关键词：Hematopoietic cell kinase ; Myelodysplastic syndrome ; Acute myeloid leukemia ; Hematopoietic stem cells ; Erythroid differentiation
• 刊名：Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：1863
• 期：2
• 页码：450-461
• 全文大小：1336 K
• 卷排序：1863

文摘

Identification of a novel Epo/HCK/PI3K/GATA-1 pathway HCK might be crucial for protection against ineffective erythropoiesis HCK is upregulated in hematopoietic stem cells cells from MDS and AML patients HCK is a probable pro-oncogene of MDS and AML with critical role in leukemogenesis HCK specific inhibitor increased leukemic cells death without affect normal hematopoietic stem cells HCK specific inhibitor represents a potential target for gene therapy